Deferasirox for iron chelation in multitransfused children with sickle cell disease; long‐term experience in the East London clinical haemoglobinopathy network

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|94|4|336-342

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.94, Iss.4, 2015-04, pp. : 336-342

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Iron Metabolism and Iron Chelation in Sickle Cell Disease

By  

Acta Haematologica, Vol. 122, Iss. 2-3, 2009-11 ,pp. : 174-183

Karger

Access to resources Recommend Favorite

Clinical Features and Long-Term Follow-Up of Quasi-Moyamoya Disease in Children

By  

Pediatric Neurosurgery, Vol. 47, Iss. 1, 2011-05 ,pp. : 15-21

Karger

Access to resources Recommend Favorite

Iron Chelation in the Treatment of Cancer: A New Role for Deferasirox?

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 53, Iss. 9, 2013-09 ,pp. : 885-891

John Wiley & Sons Inc

Access to resources Recommend Favorite

Two-Year Analysis of Efficacy and Safety of Deferasirox Treatment for Transfusional Iron Overload in Sickle Cell Anemia Patients

By  

Acta Haematologica, Vol. 128, Iss. 2, 2012-06 ,pp. : 113-118

Karger

Access to resources Recommend Favorite

Red blood cell storage duration is not associated with clinical outcomes for acute chest syndrome in children with sickle cell disease

By  

TRANSFUSION, Vol. 55, Iss. 11, 2015-11 ,pp. : 2714-2721

John Wiley & Sons Inc

Access to resources Recommend Favorite